Project: Optimizing omega-3 supplementation to resolve inflammation in a personalized medicine cardiovascular disease prevention.
| Acronym | OmegaPerMed (Reference Number: ERAPERMED2022-113) |
| Duration | 01/01/2023 - 31/12/2025 |
| Project Topic | Cardiovascular diseases (CVD) are the most common cause of death in Europe and world-wide. Optimizing CVD prevention is therefore of utmost importance, but personalized medicine has not yet reached clinical practice for CVD. Omega-3 polyunsaturated fatty acids (PUFA) are traditionally considered beneficial in CVD prevention. Clinical trials have however shown contradictory results for CVD outcomes. The aim of this project is to generate a personalized medicine CVD prevention decision tool to determine if omega-3 treatment is likely to be beneficial in individual patients, and what PUFA, dose, and formulation to use for an optimized response towards cardiovascular health.To this end, a multidisciplinary project is proposed integrating population-based genetic epidemiology, analyses of randomized clinical trials, nutrition, artificial intelligence (AI), lipidomics, and a clinical feasibility trial to identify the predictors of omega-3 PUFA responses. In five tightly connected work packages, the five partners of the consortium will explore well characterized cohorts and clinical trials for the interactions between genes, PUFA exposure, CVD risk and lipidomic markers towards beneficial CVD effects of omega-3 PUFA. Lipidomic methods, complementary between the partners, will be employed for mapping PUFA, PUFA sources, and PUFA-derived mediators as biomarkers. Data will be integrated for AI-empowered development of OmegaPerMed DSS for personalized medicine to optimize omega-3 PUFA treatment for CVD prevention, which will be continuously tested by a step-wise introduction of identified predictors in a pilot feasibility clinical trial. Ethical, legal, and social issues will be addressed throughout the project.The anticipated OmegaPerMed DSS Prevention Tool for optimizing omega-3 treatment in CVD can hence be the first personalized medicine to be widely implemented in international CVD treatment guidelines to the benefit of large patient population in Europe and world-wide. |
| Network | ERA PerMed |
| Call | 5th Joint Transnational Call for Proposals (2022) |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Institut National de la Santé et de la Recherche Médicale | Coordinator | France |
| 2 | Istituto di Ricerche Farmacologiche Mario Negri IRCCS | Partner | Italy |
| 3 | Karolinska Institutet | Partner | Sweden |
| 4 | Qlucore AB | Partner | Sweden |
| 5 | Zora Biosciences Oy | Partner | Finland |